Tracked deals
4
4 tracked deals across 2019-2025.
Public Company
Healthcare
Revvity
Waltham, Massachusetts, United States
Formerly known as Perkin Elmer, PerkinElmer, PerkinElmer Inc.
Revvity is a scientific solutions company providing technology, instruments, reagents, and services that enable customers to measure, analyze, and support quality, safety, and performance across life sciences, diagnostics, food, and environmental applications.
- Focus Areas
- Analytical instruments, Laboratory technologies and solutions, Reagents, assays, and related consumables
- Website
- www.revvity.com
Recent pace
0
0 tracked deals announced in the last 12 months.
Deal mix
Buyout
3 buyout · 1 addon
Revvity Acquisition Volume by Year
Last 4 years
Supporting Data
Recent Transactions
-
March 11, 2025
- Buyer
- PerkinElmer
- Target
- Project Farma
- Seller
- Precision for Medicine
- Industry
- Healthcare Services
- Location
- Connecticut, United States
- Type
- Buyout
PerkinElmer announced the acquisition of Project Farma, a life sciences consultancy focused on advancing technical operations from ideation through commercialization. The deal expands PerkinElmer’s OneSource professional services offering for the life sciences value chain.
-
December 8, 2023
- Buyer
- PerkinElmer
- Target
- Covaris
- Industry
- Medical Devices
- Location
- Massachusetts, United States
- Type
- Addon
PerkinElmer has acquired Covaris, a Woburn, Massachusetts-based developer of instruments, consumables, and reagents for high-throughput genomic and proteomic sample preparation. Both companies are majority owned by New Mountain Capital; the acquisition expands PerkinElmer's life-sciences portfolio and accelerates its entry into the diagnostics and NGS sample-preparation market. Terms were not disclosed.
-
- Buyer
- PerkinElmer, Inc.
- Target
- BioLegend
- Industry
- Biotechnology
- Location
- California, United States
- Type
- Buyout
PerkinElmer, Inc. agreed to acquire BioLegend, a leading developer of antibodies and life-science reagents, for approximately $5.25 billion in cash and stock. The acquisition expands PerkinElmer's life-science franchise into high-growth areas such as biologics, cell and gene therapy, and proteogenomics, and is expected to be accretive to earnings.
-
April 26, 2019
- Buyer
- PerkinElmer
- Target
- Cisbio Bioassays
- Seller
- Abénex Capital SA, Cisbio management
- Industry
- Biotechnology
- Location
- Occitanie, France
- Type
- Buyout
PerkinElmer has acquired Cisbio Bioassays from Abénex (with Cisbio management supporting the sale). Cisbio, headquartered in Codolet, France, is a manufacturer of HTRF assay kits, reagents and custom assay services with more than 200 employees; the acquisition expands PerkinElmer's life‑sciences reagent and screening technology portfolio.
Related Acquisition Pages
Biotechnology Buyers & Acquisitions
2 tracked deals by Revvity.
Healthcare Services Buyers & Acquisitions
1 tracked deal by Revvity.
Medical Devices Buyers & Acquisitions
1 tracked deal by Revvity.
Acquisitions in California
1 tracked deal by Revvity.
Acquisitions in Connecticut
1 tracked deal by Revvity.
Acquisitions in Massachusetts
1 tracked deal by Revvity.
Selling a company? Get in front of buyers like Revvity
Turn tracked acquisition activity into an outreach-ready buyer list.